Lead Manager on ArriVent Biopharma's Confidentially Marketed Public Offering

Oppenheimer & Co. Inc. acted as Lead Manager on ArriVent Biopharma’s $86.3MM Confidentially Marketed Public Offering

ArriVent BioPharma, Inc. (“ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, announced the pricing of an underwritten confidentially marketed public offering of 3,059,615 shares of its common stock at a price to the public of $19.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 1,363,469 shares of its common stock at a price to the public of $19.4999, which represents the per share confidentially marketed public offering price for the shares of common stock less $0.0001 per share exercise price for each pre-funded warrant. The gross proceeds to ArriVent from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be approximately $86.3 million.

ArriVent intends to use the net proceeds from the offering, together with its existing cash resources, to support its activities for firmonertinib and its other pipeline programs and for working capital and other general corporate purposes.